New views on cellular uptake and trafficking of manufactured nanoparticles

Journal of the Royal Society Interface

Volumn 10, Issue 82, 2013, Pages

  Treuel, Lennart ^a,b   Jiang, Xiue ^c   Nienhaus, Gerd Ulrich ^a,d,e  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^d KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^e University of Illinois at Urbana Champaign   (United States)

Author keywords

Cellular uptake; Drug delivery; Endocytosis; Exocytosis; Nanoparticles

Indexed keywords

CELL ENGINEERING; DRUG DELIVERY; FLUORESCENCE MICROSCOPY; MOLECULAR BIOLOGY; NANOPARTICLES; PROTEINS;

ADVERSE HEALTH EFFECTS; BIOLOGICAL ENVIRONMENTS; CELLULAR COMPONENTS; CELLULAR UPTAKE; ENDOCYTOSIS; EXOCYTOSIS; MANUFACTURED NANOPARTICLES; TARGETED DRUG DELIVERY;

NANOCONJUGATES;

CONTRAST MEDIUM; NANOPARTICLE;

ADSORPTION; CELL LABELING; CELL METABOLISM; CELL MIGRATION; CONFORMATIONAL TRANSITION; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INTERNALIZATION; MICROSCOPY; MOLECULAR INTERACTION; MOLECULAR MODEL; REVIEW; ACTIVE TRANSPORT; DRUG DELIVERY SYSTEM; HELA CELL;

BIOLOGICAL TRANSPORT, ACTIVE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HELA CELLS; HUMANS; NANOPARTICLES;

MLCS; MLOWN;

EID: 84881308513     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2012.0939     Document Type: Review

References (113)

1. Ye-Qin Z, Wang Y-F, Jiang X-D. 2008 The application of nanoparticles in biochips. Recent Patent Biotechnol. 2, 55-59. (doi:10.2174/187220808783330938)
2. OECD. 2008 Current developments/activities on the safety of manufactured nanomaterials. Paris, France: OECD.
3. Roco MC. 2008 The journal of nanoparticle research at 10 years. J. Nanoparticle Res. 10, 1-2. (doi:10.1007/s11051-008-9528-3)
4. Aitken RJ, Chaudhry MQ, Boxall ABA, Hull M. 2006 Manufacture and use of nanomaterials: current status in the UK and global trends. Occup. Med. 56, 300-306. (doi:10.1093/occmed/kql051)
5. Anselmann R. 2001 Nanoparticles and nanolayers in commercial applications. J. Nanoparticle Res. 3, 329-336. (doi:10.1023/A:1017529712314)
6. Handy RD, Henry TB, Scrown TM, Johnston BD, Tyler CR. 2008 Manufactured nanoparticles: their uptake and effects on fish: a mechanistic analysis. Ecotoxicology 17, 396-409. (doi:10.1007/s10646-008-0205-1)
7. Wiesner MR, Lowry GV, Alvarez P, Dionysiou D, Biswas P. 2006 Assessing the risks of manufactured nanomaterials. Environ. Sci. Technol. 40, 4336-4345. (doi:10.1021/es062726m)
8. Owen R, Depledge M. 2005 Nanotechnology in the environment: risks and rewards. Mar. Pollut. Bull. 50, 609-612. (doi:10.1016/j.marpolbul.2005.05.001)
9. Kreyling WG, Semmler M, Möller W. 2004 Dosimetry and toxicology of ultrafine particles. J. Aerosol Med. 17, 140-152. (doi:10.1089/0894268041457147)
10. Treuel L, Nienhaus GU. 2012 Toward a molecular understanding of nanoparticle-protein interactions. Biophys. Rev. 4, 137-147. (doi:10.1007/s12551-012-0072-0)
11. 2 nanoparticles for radiotracer studies. J. Nanoparticle Res. 12, 2435-2443. (doi:10.1007/s11051-009-9806-8)
12. Keller KH. 2007 Nanotechnology and society. J. Nanoparticle Res. 9, 5-10. (doi:10.1007/s11051-006-9193-3)
13. Maynard AD et al. 2006 Safe handling of nanotechnology. Nature 444, 267-269. (doi:10.1038/444267a)
14. Nel A, Xia T, Mädler L, Li N. 2006 Toxic potential of materials at the nanolevel. Science 311, 622-627. (doi:10.1126/science.1114397)
15. Service RF. 2006 Priorities needed for nano-risk research and development. Science 314, 45. (doi:10.1126/science.314.5796.45)
16. Barnard AS. 2006 Nanohazards: knowledge is our first defence. Nat. Mater. 5, 245-248. (doi:10.1038/nmat1615)
17. Handy RD, von der Kammer F, Lead JR, Hassellöv M, Owen R, Crane M. 2008 The ecotoxicology and chemistry of manufactured nanoparticles. Ecotoxicology 17, 287-314. (doi:10.1007/s10646-008-0199-8)
18. Linse S, Cabaleiro-Lago C, Xue W-F, Lynch I, Lindman S, Thulin E, Radford SE, Dawson KA. 2007 Nucleation of protein fibrillation by nanoparticles. Proc. Natl Acad. Sci. USA 104, 8691-8696. (doi:10.1073/pnas.0701250104)
19. Lunov O, Zablotskii V, Syrovets T, Röcker C, Tron K, Nienhaus GU, Simmet T. 2011 Modeling receptormediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. Biomaterials 32, 547-555. (doi:10.1016/j.biomaterials.2010.08.111)
20. Lunov O, Syrovets T, Röcker C, Tron K, Nienhaus GU, Rasche V, Mailänder V, Landfester K, Simmet T. 2010 Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 31, 9015-9022. (doi:10.1016/j.biomaterials.2010.08.003)
21. Asha Rani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. 2008 Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3, 279-290. (doi:10.1021/nn800596w)
22. Conner S, Schmid SL. 2003 Regulated portals of entry into the cell. Nature 422, 37-44. (doi:10.1038/nature01451)
23. Jiang X, Musyanovych A, Röcker C, Landfester K, Mailänder V, Nienhaus GU. 2011 Specific effects of surface carboxyl groups on anionic polystyrene particles in their interactions with mesenchymal stem cells. Nanoscale 3, 2028-2035. (doi:10.1039/c0nr00944j)
24. Chithrani BD, Ghazani AA, Chan WCW. 2006 Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662-668. (doi:10.1021/nl052396o)
25. Rejman J, Oberle V, Zuhorn I, Hoekstra D. 2004 Sizedependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159-169. (doi:10.1042/BJ20031253)
26. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. 1998 Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J. Pharm. Sci. 87, 1229-1234. (doi:10.1021/js980021f)
27. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA. 2003 Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 229, 838-846. (doi:10.1148/radiol.2293021215)
28. Sun XK, Rossin R, Turner JL, Becker ML, Joralemon MJ, Welch MJ, Wooley KJ. 2005 An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 6, 2541-2554. (doi:10.1021/bm050260e)
29. Nativo P, Prior IA, Brust M. 2008 Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2, 1639-1644. (doi:10.1021/ nn800330a)
30. Holzapfel V, Lorenz M, Weiss CK, Schrezenmeier H, Landfester K, Mailänder V. 2006 Synthesis and biomedical applications of functionalized fluorescent and magnetic dual reporter nanoparticles as obtained in the mini emulsion process. J. Phys. Condensed Matter 18, S2581-S2594. (doi:10.1088/0953-8984/18/38/S04)
31. de Paoli Lacerda SH, Park JJ, Meuse C, Pristinski D, Becker ML, Karim A, Douglas J. 2010 Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4, 365-379. (doi:10.1021/nn9011187)
32. Cedervall T, Lynch I, Foy M, Berggård T, Donnelly SC, Cagney G, Linse S, Dawson KA. 2007 Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. 46, 5754-5756. (doi:10.1002/anie.200700465)
33. Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson KA, Linse S. 2007 Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050-2055. (doi:10.1073/pnas.0608582104)
34. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. 2008 Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105, 14 265-14 270. (doi:10.1073/pnas.0805135105)
35. Lynch I. 2007 Are there generic mechanisms governing interactions between nanoparticles and cells? Random epitope mapping for the outer layer of the protein-material interface. Physica A 373, 511-520. (doi:10.1016/j.physa.2006. 06.008)
36. Röcker C, Pötzl M, Zhang F, Parak WJ, Nienhaus GU. 2009 A quantitative fluoresence study of protein monolayer formation on colloidal nanoparticles. Nat. Nanotechnol. 4, 577-580. (doi:10.1038/nnano.2009.195)
37. Shang L, Brandholt S, Stockmar F, Trouillet V, Bruns M, Nienhaus GU. 2012 Effect of protein adsorption on the fluorescence of ultrasmall gold nanoclusters. Small 8, 661-665. (doi:10.1002/smll.201101353)
38. Shang L, Wang Y, Jiang J, Dong S. 2007 pHdependent protein conformational changes in albumin:gold nanoparticle bioconjugates: a spectroscopic study. Langmuir 23, 2714-2721. (doi:10.1021/la062064e)
39. Gebauer JS, Malissek M, Simon S, Knauer SK, Maskos M, Stauber RH, Peukert W, Treuel L. 2012 Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir 28, 9181-9906. (doi:10.1021/la300292r)
40. Treuel L, Malissek M, Gebauer JS, Zellner R. 2010 The influence of surface composition of nanoparticles on their interactions with serum albumin. Chem. Phys. Chem. 11, 3093-3099. (doi:10.1002/cphc.201000174)
41. Treuel L, Malissek M, Grass S, Diendorf J, Mahl D, Meyer-Zaika W, Epple M. 2012 Quantifying the influence of polymer coatings on the serum albumin corona formation around silver and gold nanoparticles. J. Nanoparticle Res. 14, 1102-1104. (doi:10.1007/s11051-012-1102-3)
42. Monopoli MP, A°berg C, Salvati A, Dawson KA. 2012 Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779-786. (doi:10.1038/nnano.2012.207)
43. Pitek AS, O'Connell D, Mahon E, Monopoli MP, Baldelli Bombelli F, Dawson KA. 2012 Transferrin coated nanoparticles: study of the bionano interface in human plasma. PLoS ONE 7, e40685. (doi:10.1371/journal.pone.0040685)
44. Wang T, Bai J, Jiang X, Nienhaus GU. 2012 Cellular uptake of nanoparticles by membrane penetration: a study combining confocal microscopy with FTIR spectroelectrochemistry. ACS Nano 6, 1251-1259. (doi:10.1021/ nn203892h)
45. Rothen-Rutishauser BM, Schürch S, Haenni B, Kapp N, Gehr P. 2006 Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ. Sci. Technol. 40, 4353-4359. (doi:10.1021/es0522635)
46. Verma A, Uzun O, Hu Y, Hu Y, Han H-S, Watson N, Chen S, Irvine DJ, Stellacci F. 2008 Surface-structureregulated cell-membrane penetration by monolayerprotected nanoparticles. Nat. Mater. 7, 588-595. (doi:10.1038/nmat2202)
47. Zhang X, Yang S. 2011 Nonspecific adsorption of charged quantum dots on supported zwitterionic lipid bilayers: real-time monitoring by quartz crystal microbalance with dissipation. Langmuir 27, 2528-2535. (doi:10.1021/la104449y)
48. Dif A, Henry E, Artzner F, Baudy-Floćh M, Schmutz M, Dahan M, Marchi-Artzner V. 2008 Interaction between water-soluble peptidic CdSe/ZnS nanocrystals and membranes: formation of hybrid vesicles and condensed lamellar phases. J. Am. Chem. Soc. 130, 8289-8296. (doi:10.1021/ja711378g)
49. Laurencin M, Georgelin T, Malezieux B, Siaugue J-M, Ménager C. 2010 Interactions between giant unilamellar vesicles and charged core-shell magnetic nanoparticles. Langmuir 26, 16 025-16 030. (doi:10.1021/la1023746)
50. Leroueil PR, Hong S, Mecke A, Baker JR, Orr BG, Banaszak Holl MM. 2007 Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc. Chem. Res. 40, 335-342. (doi:10.1021/ar600012y)
51. Roiter Y, Ornatska M, Rammohan AR, Balakrishnan J, Heine DR, Minko S. 2008 Interaction of nanoparticles with lipid membrane. Nano Lett. 8, 941-944. (doi:10.1021/nl080080l)
52. Leroueil PR, Berry SA, Duthie K, Han G, Rotello VM, McNerny DQ, Baker JR, Orr BG, Banaszak Holl MM. 2008 Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett. 8, 420-424. (doi:10.1021/ nl0722929)
53. Yu J, Patel SA, Dickson RM. 2007 In vitro and intracellular production of peptide-encapsulated fluorescent silver nanoclusters. Angew. Chem. Int. Ed. 46, 2028-2030. (doi:10.1002/anie.200604253)
54. Kostarelos K et al. 2007 Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2, 108-113. (doi:10.1038/nnano.2006.209)
55. 2/KI etchant. Nano Lett. 9, 1080-1084. (doi:10.1021/nl803487r)
56. Zhao Y, Sun X, Zhang G, Trewyn BG, Slowing II, Lin VSY. 2011 Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. ACS Nano 5, 1366-1375. (doi:10.1021/nn103077k)
57. Lin J, Zhang H, Chen Z, Zheng Y. 2010 Penetration of lipid membranes by gold nanoparticles: insights into cellular uptake, cytotoxicity, and their relationship. ACS Nano 4, 5421-5429. (doi:10.1021/nn1010792)
58. Stohs SJ, Bagchi D. 1995 Oxidative mechanisms in the toxicity of metal ions. Free Radic. Biol. Med. 18, 321-336. (doi:10.1016/0891-5849(94)00159-H)
59. Silver S. 1996 Bacterial resistances to toxic metal ions: a review. Gene 179, 9-19. (doi:10.1016/S0378-1119(96)00323-X)
60. Ratte HT. 1999 Bioaccumulation and toxicity of silver compounds: a review. Environ. Toxicol. Chem. 18, 89-108. (doi:10.1002/etc.5620180112)
61. Kittler S et al. 2010 The influence of proteins on the dispersability and cell-biological activity of silver nanoparticles. J. Mater. Chem. 20, 512-518. (doi:10.1039/b914875b)
62. Kittler S, Greulich C, Diendorf J, Köller M, Epple M. 2010 The toxicity of silver nanoparticles increases during storage due to slow dissolution under release of silver ions. Chem. Mater. 22, 4548-4554. (doi:10.1021/cm100023p)
63. Greulich C, Kittler S, Epple M, Muhr G, Köller M. 2009 Studies on the biocompatibility and the interaction of silver nanoparticles with human mesenchymal stem cells (hMSCs). Langenbecks Arch. Surg. 394, 495-502. (doi:10.1007/s00423-009-0472-1)
64. Jiang X, Weise S, Hafner M, Röcker C, Zhang F, Parak WJ, Nienhaus GU. 2010 Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding. J. R. Soc. Interface 7, S5-S13. (doi:10.1098/rsif.2009.0272.focus)
65. Owens DE, Peppas NA. 2006 Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102. (doi:10.1016/j.ijpharm.2005.10.010)
66. Kah JC, Wong KY, Neoh KG, Song JH, Fu JW, Mhaisalkar S, Olivo M, Sheppard CJ. 2009 Critical parameters in the PEGylation of gold nanoshells for biomedical applications: an in vitro macrophage study. J. Drug Target. 17, 181-193. (doi:10.1080/10611860802582442)
67. Klein J. 2007 Probing the interactions of proteins and nanoparticles. Proc. Natl Acad. Sci. USA 104, 2029-2030. (doi:10.1073/pnas.0611610104)
68. Maffre P, Nienhaus K, Amin F, Parak WJ, Nienhaus GU. 2011 Characterization of protein adsorption onto FePt nanoparticles using dual-focus fluorescence correlation spectroscopy. Beilstein J. Nanotechnol. 2, 374-383. (doi:10.3762/bjnano.2.43)
69. Frauenfelder H, Nienhaus GU, Johnson JB. 1991 Rate-processes in proteins. Ber. Bunsen Phys. Chem. 95, 272-278. (doi:10.1002/bbpc.19910950310)
70. Nienhaus GU, Heinzl J, Huenges E, Parak F. 1989 Protein crystal dynamics studied by time-resolved analysis of X-ray diffuse scattering. Nature 338, 665-666. (doi:10.1038/338665a0)
71. Prapainop K, Witter DP, Wentworth P. 2012 A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. J. Am. Chem. Soc. 134, 4100-4103. (doi:10.1021/ja300537u)
72. Prapainop K, Wentworth Jr P. 2011 A shotgun proteomic study of the protein corona associated with cholesterol and atheronal-B surface-modified quantum dots. Eur. J. Pharm. Biopharm. 77, 353-359. (doi:10.1016/j.ejpb.2010.12. 026)
73. Wentworth P et al. 2003 Evidence for ozone formation in human atherosclerotic arteries. Science 302, 1053-1056. (doi:10.1126/science.1089525)
74. Scheinost JC, Wang H, Boldt GE, Offer J, Wentworth P. 2008 Cholesterol seco-sterol-induced aggregation of methylated amyloid-β peptides: insights into aldehyde-initiated fibrillization of amyloid-β. Angew. Chem. Int. Ed. 47, 3919-3922. (doi:10.1002/anie.200705922)
75. Bieschke J, Zhang Q, Bosco DA, Lerner RA, Powers ET, Wentworth P, Kelly JW. 2006 Small molecule oxidation products trigger disease-associated protein misfolding. Acc. Chem. Res. 39, 611-619. (doi:10.1021/ar0500766)
76. Nieva J, Shafton A, Altobell LJ, Tripuraneni S, Rogel JK, Wentworth AD, Lerner RA, Wentworth P. 2008 Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation. Biochemistry 47, 7695-7705. (doi:10.1021/bi800333s)
77. Scheinost JC, Witter DP, Boldt GE, Offer J, Wentworth P. 2009 Cholesterol secosterol adduction inhibits the misfolding of a mutant prion protein fragment that induces neurodegeneration. Angew. Chem. Int. Ed. 48, 9469-9472. (doi:10.1002/anie.200904524)
78. Dausend J, Musyanovych A, Dass M, Walther P, Schrezenmeier H, Landfester K, Mailänder V. 2008 Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol. Biosci. 8, 1135-1143. (doi:10.1002/mabi.200800123)
79. Jiang W, Kim BYS, Rutka JT, Chan WCW. 2008 Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145-150. (doi:10.1038/nnano. 2008.30)
80. Storm G, Belliot SO, Daemen T, Lasic DD. 1995 Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Del. Rev. 17, 31-48. (doi:10.1016/0169-409X(95)00039-A)
81. Chavanpatil MD, Khdair A, Panyam J. 2006 Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J. Nanosci. Nanotechnol. 6, 2651-2663. (doi:10.1166/jnn.2006.443)
82. Kim JA, A°berg C, Salvati A, Dawson KA. 2012 Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 7, 62-68. (doi:10.1038/nnano.2011.191)
83. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. 2006 Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839-850. (doi:10.1016/j.devcel.2006.04.002)
84. Wang L, Rothberg K, Anderson R. 1993 Misassembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol. 123, 1107-1117. (doi:10.1083/jcb.123.5.1107)
85. Larkin J, Brown M, Goldstein J, Anderson R. 1983 Depletion of intracellular potassium arrests coated pit formation and receptor-mediated endocytosis in fibroblasts. Cell 33, 273-285. (doi:10.1016/0092-8674(83)90356-2)
86. Sandin P, Fitzpatrick LW, Simpson JC, Dawson KA. 2012 High-speed imaging of rab family small GTPases reveals rare events in nanoparticle trafficking in living cells. ACS Nano 6, 1513-1521. (doi:10.1021/nn204448x)
87. Stenmark H. 2009 Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10, 513-525. (doi:10.1038/nrm2728)
88. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. 2005 Rab conversion as a mechanism of progression from early to late endosomes. Cell 122, 735-749. (doi:10.1016/j.cell.2005.06.043)
89. Feng Y, Press B, Wandinger-Ness A. 1995 Rab 7: an important regulator of late endocytic membrane traffic. J. Cell Biol. 131, 1435-1452. (doi:10.1083/jcb.131.6.1435)
90. Vanlandingham PA, Ceresa BP. 2009 Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J. Biol. Chem. 284, 12 110-12 124. (doi:10.1074/jbc.M809277200)
91. Lombardi D, Soldati T, Riederer MA, Goda Y, Zerial M, Pfeffer SR. 1993 Rab9 functions in transport between late endosomes and the trans Golgi network. EMBO J. 12, 677-682.
92. Ullrich O, Reinsch S, Urbé S, Zerial M, Parton RG. 1996 Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol. 135, 913-924. (doi:10.1083/jcb.135.4.913)
93. Simpson JC, Griffiths G, Wessling-Resnick M, Fransen JAM, Bennett H, Jones AT. 2004 A role for the small GTPase Rab21 in the early endocytic pathway. J. Cell Sci. 117, 6297-6311. (doi:10.1242/jcs.01560)
94. Jiang X, Röcker C, Hafner M, Brandholt S, Dörlich RM, Nienhaus GU. 2010 Endo- and exocytosis of zwitterionic quantum dot nanoparticles by live HeLa cells. ACS Nano 4, 6787-6797. (doi:10.1021/nn101277w)
95. Salvati A, A°berg C, dos Santos T, Varela J, Pinto P, Lynch I, Dawson KA. 2011 Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics. Nanomed. Nanotechnol. 7, 818-826. (doi:10.1016/j.nano.2011.03.005)
96. Lesniak A, Campbell A, Monopoli MP, Lynch I, Salvati A, Dawson KA. 2010 Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials 31, 9511-9518. (doi:10.1016/j.biomaterials.2010.09.049)
97. Shapero K, Fenaroli F, Lynch I, Cottell DC, Salvati A, Dawson KA. 2011 Time and space resolved uptake study of silica nanoparticles by human cells. Mol. Biosyst. 7, 371-378. (doi:10.1039/c0mb00109k)
98. Gebauer JS, Treuel L. 2011 Influence of individual ionic components on the agglomeration kinetics of silver nanoparticles. J. Colloid Interface Sci. 354, 546-554. (doi:10.1016/j.jcis.2010.11.016)
99. Cho EC, Zhang Q, Xia Y. 2011 The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotechnol. 6, 385-391. (doi:10.1038/nnano.2011.58)
100. Gao H, Shi W, Freund LB. 2005 Mechanics of receptor-mediated endocytosis. Proc. Natl Acad. Sci. USA 102, 9469-9474. (doi:10.1073/pnas.0503879102)
101. Pitas RE, Friera A, McGuire J, Dejager S. 1992 Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler. Thromb. Vasc. Biol. 12, 1235-1244. (doi:10.1161/01.ATV.12.11.1235)
102. Mühlfeld C, Gehr P, Rothen-Rutishauser B. 2008 Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med. Wkly. 138, 387-391.
103. Geiser M et al. 2005 Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ. Health Perspect. 113, 1555-1560. (doi:10.1289/ehp.8006)
104. Underhill DM, Ozinsky A. 2002 Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20, 825-852. (doi:10.1146/annurev.immunol.20.103001. 114744)
105. Jiang X, Zaitseva E, Schmidt M, Siebert F, Engelhard M, Schlesinger R, Ataka K, Vogel R, Heberle J. 2008 Resolving voltage-dependent structural changes of a membrane photoreceptor by surface-enhanced IR difference spectroscopy. Proc. Natl Acad. Sci. USA 105, 12 113-12 117. (doi:10.1073/pnas.0802289105)
106. Osawa M. 2001 Surface-enhanced infrared absorption. Top. Appl. Phys. 81, 163-187. (doi:10.1007/3-540-44552-8-9)
107. Herbig ME, Assi F, Textor M, Merkle HP. 2006 The cell penetrating peptides pVEC and W2-pVEC induce transformation of gel phase domains in phospholipid bilayers without affecting their integrity. Biochemistry 45, 3598-3609. (doi:10.1021/bi050923c)
108. Thorén PEG, Persson D, Isakson P, Goksör M, Önfelt A, Nordén B. 2003 Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem. Biophys. Res. Commun. 307, 100-107. (doi:10.1016/S0006-291X(03)01135-5)
109. Patel L, Zaro J, Shen W-C. 2007 Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 24, 1977-1992. (doi:10.1007/s11095-007-9303-7)
110. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. 2010 Time evolution of the nanoparticle protein corona. ACS Nano 4, 3623-3632. (doi:10.1021/ nn901372t)
111. Oberdörster G. 2010 Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 267, 89-105. (doi:10.1111/j.1365-2796.2009.02187.x)
112. Chithrani BD, Chan WCW. 2007 Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542-1550. (doi:10.1021/nl070363y)
113. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdörster G, McGrath JL. 2009 The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30, 603-610. (doi:10.1016/j. biomaterials.2008.09.050)